PL2224917T3 - Kompozycja zawierająca nikotynę oraz opipramol i jej zastosowanie - Google Patents
Kompozycja zawierająca nikotynę oraz opipramol i jej zastosowanieInfo
- Publication number
- PL2224917T3 PL2224917T3 PL08855517T PL08855517T PL2224917T3 PL 2224917 T3 PL2224917 T3 PL 2224917T3 PL 08855517 T PL08855517 T PL 08855517T PL 08855517 T PL08855517 T PL 08855517T PL 2224917 T3 PL2224917 T3 PL 2224917T3
- Authority
- PL
- Poland
- Prior art keywords
- opipramol
- nicotine
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US99016107P | 2007-11-26 | 2007-11-26 | |
EP08855517.2A EP2224917B1 (en) | 2007-11-26 | 2008-11-26 | Composition comprising nicotine and opipramol and use thereof |
PCT/IL2008/001546 WO2009069126A1 (en) | 2007-11-26 | 2008-11-26 | Compositions comprising nicotinic agonists and methods of using same |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2224917T3 true PL2224917T3 (pl) | 2018-02-28 |
Family
ID=40380297
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL08855517T PL2224917T3 (pl) | 2007-11-26 | 2008-11-26 | Kompozycja zawierająca nikotynę oraz opipramol i jej zastosowanie |
Country Status (21)
Country | Link |
---|---|
US (5) | US8273731B2 (pl) |
EP (1) | EP2224917B1 (pl) |
JP (1) | JP5456687B2 (pl) |
KR (1) | KR101613742B1 (pl) |
CN (1) | CN101925352B (pl) |
AR (1) | AR069752A1 (pl) |
AU (1) | AU2008331102B2 (pl) |
BR (1) | BRPI0819911A2 (pl) |
CA (1) | CA2744736C (pl) |
CL (1) | CL2008003507A1 (pl) |
CY (1) | CY1119768T1 (pl) |
DK (1) | DK2224917T3 (pl) |
ES (1) | ES2642873T3 (pl) |
HR (1) | HRP20171476T1 (pl) |
HU (1) | HUE035105T2 (pl) |
LT (1) | LT2224917T (pl) |
MX (1) | MX2010005804A (pl) |
PL (1) | PL2224917T3 (pl) |
PT (1) | PT2224917T (pl) |
SI (1) | SI2224917T1 (pl) |
WO (1) | WO2009069126A1 (pl) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CL2008003507A1 (es) | 2007-11-26 | 2009-11-27 | Neuroderm Ltd | Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico. |
KR101563554B1 (ko) | 2008-08-01 | 2015-10-27 | 퀄컴 테크놀로지스, 인크. | 잡음 제거를 위한 통합 시간 필터를 구비한 비디오 인코더 |
US9801865B2 (en) * | 2008-09-24 | 2017-10-31 | The United States Of America As Represented By The Department Of Veteran Affairs | Materials and methods for diagnosis, prevention and/or treatment of stress disorders and conditions associated with abeta peptide aggregation |
US8529914B2 (en) * | 2010-06-28 | 2013-09-10 | Richard C. Fuisz | Bioactive dose having containing a material for modulating pH of a bodily fluid to help or hinder absorption of a bioactive |
DK2701681T3 (en) | 2011-04-29 | 2017-01-09 | Moberg Pharma Ab | PHARMACEUTICAL COMPOSITIONS COMPRISING A LOCAL ANESTHETICS as bupivacaine for local administration to the mouth or throat |
JP6566867B2 (ja) * | 2012-07-13 | 2019-08-28 | ペイン セラピューティクス インコーポレイテッド | 生きている患者でのアルツハイマー病アッセイ |
US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
ES2967693T3 (es) | 2014-03-13 | 2024-05-03 | Neuroderm Ltd | Composiciones del inhibidor de la dopa descarboxilasa |
US20170216273A1 (en) * | 2014-05-29 | 2017-08-03 | Jory F. Goodman | Nicotine Derivatives and Methods of Use |
EP3193849A1 (en) * | 2014-09-18 | 2017-07-26 | Neuroderm, Ltd. | Opipramol patch |
JP6873906B2 (ja) * | 2014-10-20 | 2021-05-19 | オイスター ポイント ファーマ インコーポレイテッド | 眼の病状の治療方法 |
EP3821735A1 (en) | 2014-12-05 | 2021-05-19 | Juul Labs, Inc. | Calibrated dose control |
EP3970724A1 (en) | 2016-04-07 | 2022-03-23 | Oyster Point Pharma, Inc. | Methods of treating ocular conditions |
US10292977B2 (en) * | 2016-04-11 | 2019-05-21 | Neurocea, LLC | Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases |
MX2018012439A (es) * | 2016-04-12 | 2019-02-21 | Solis Herrera Arturo | Composiciones y metodos para el tratamiento de enfermedades de la mucosa nasal y paranasal con agonistas del receptor de acetilcolina de tipo nicotinico. |
WO2018097629A1 (ko) * | 2016-11-24 | 2018-05-31 | 에스케이케미칼 주식회사 | 바레니클린 서방성 제제 및 이의 제조 방법 |
WO2018150276A2 (en) | 2017-02-16 | 2018-08-23 | Universidad San Sebastian | The combination of cotinine plus antioxidant for treatment-resistant depression and correction of astrocytes functional deficit induced by depression and other neuropathological conditions |
WO2018156883A1 (en) * | 2017-02-23 | 2018-08-30 | Board Of Regents, The University Of Texas System | Methods of treatment for cancer, sterol homeostasis, and neurological diseases |
AU2018364738A1 (en) * | 2017-11-10 | 2020-05-28 | Howard Hughes Medical Institute | Modified ligand-gated ion channels and methods of use |
LU101519B1 (en) * | 2019-12-02 | 2021-06-07 | Herrera Arturo Solis | (S)-3-[1-MethyIpyrrolidin-2-yl]pyridine, analogues thereof, precursors thereof, or its derivatives, for the use as a pharmaceutical in form of a solid substance and a tablet |
US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5069094A (en) | 1987-09-08 | 1991-12-03 | Birkestrand Orville J | Tube end finishing machine |
US5656286A (en) | 1988-03-04 | 1997-08-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
US5668117A (en) | 1991-02-22 | 1997-09-16 | Shapiro; Howard K. | Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments |
US5336675A (en) | 1991-05-14 | 1994-08-09 | Ernir Snorrason | Method of treating mania in humans |
WO1993023045A1 (en) * | 1992-05-18 | 1993-11-25 | Pharmaco Behavioral Associates, Inc. | Use of cotinine to alleviate tobacco withdrawal syndrome |
JPH09262287A (ja) * | 1996-03-28 | 1997-10-07 | Terumo Corp | 薬液注入装置 |
EP1006798A4 (en) | 1996-09-05 | 2003-03-05 | Massachusetts Inst Technology | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS AND NEURODEGENERATIVE DISEASES |
DE10018834A1 (de) * | 2000-04-15 | 2001-10-25 | Lohmann Therapie Syst Lts | Transdermale oder transmucosale Darreichungsformen mit einer nicotinhaltigen Wirkstoffkombination zur Raucherentwöhnung |
US20070225379A1 (en) * | 2001-08-03 | 2007-09-27 | Carrara Dario Norberto R | Transdermal delivery of systemically active central nervous system drugs |
AU2001282064B2 (en) | 2000-08-03 | 2007-02-01 | Antares Pharma Ipl Ag | Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels |
US6479076B2 (en) * | 2001-01-12 | 2002-11-12 | Izhak Blank | Nicotine delivery compositions |
DE10134038A1 (de) | 2001-07-12 | 2003-02-06 | Hf Arzneimittelforsch Gmbh | Wirkstoff-Kombination zur medikamentösen Therapie der Nikotinabhängigkeit |
US20030119879A1 (en) * | 2001-10-15 | 2003-06-26 | Thomas Landh | Nicotine and chocolate compositions |
US6852741B2 (en) | 2001-12-31 | 2005-02-08 | University Of Florida | Compositions and methods for treatment of neurological disorders |
US7045534B2 (en) | 2002-02-12 | 2006-05-16 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of reducing angiogenesis |
WO2004056305A2 (en) * | 2002-12-18 | 2004-07-08 | Algorx | Administration of capsaicinoids |
ITMI20030828A1 (it) | 2003-04-18 | 2004-10-19 | Farchemia Srl | Procedimento per la preparazione dell'opipramolo. |
PT1670433E (pt) | 2003-10-10 | 2012-02-08 | Ferring Bv | Fórmula farmacológica transdérmica para a minimização de resíduos na pele |
CA2551946A1 (en) | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Immediate, controlled and sustained release formulations of galantamine |
US20050234024A1 (en) * | 2004-04-14 | 2005-10-20 | Clarke David E | Materials and methods for the treatment of ulcerative colitis |
WO2005115471A2 (en) | 2004-05-27 | 2005-12-08 | Neurocure Ltd. | Methods and compositions for treatment of nicotine dependence and dementias |
US20060142349A1 (en) * | 2004-12-23 | 2006-06-29 | Pfizer Inc | Methods of modulating the activities of alpha-7 nicotinic acetylcholine receptor |
US20080014252A1 (en) | 2006-07-14 | 2008-01-17 | Delprete Keith | Topical compositions with long lasting effect |
CN101534833B (zh) | 2006-07-18 | 2013-03-13 | 贝塞斯达药理学联合有限责任公司 | 烟碱脱敏剂及选择、测试及使用它们的方法 |
WO2008028903A2 (en) * | 2006-09-04 | 2008-03-13 | Neurosearch A/S | Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer |
CL2008003507A1 (es) * | 2007-11-26 | 2009-11-27 | Neuroderm Ltd | Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico. |
-
2008
- 2008-11-25 CL CL2008003507A patent/CL2008003507A1/es unknown
- 2008-11-26 DK DK08855517.2T patent/DK2224917T3/en active
- 2008-11-26 AR ARP080105141A patent/AR069752A1/es not_active Application Discontinuation
- 2008-11-26 PT PT88555172T patent/PT2224917T/pt unknown
- 2008-11-26 EP EP08855517.2A patent/EP2224917B1/en not_active Not-in-force
- 2008-11-26 PL PL08855517T patent/PL2224917T3/pl unknown
- 2008-11-26 CN CN200880126096.9A patent/CN101925352B/zh not_active Expired - Fee Related
- 2008-11-26 KR KR1020107014088A patent/KR101613742B1/ko not_active IP Right Cessation
- 2008-11-26 LT LTEP08855517.2T patent/LT2224917T/lt unknown
- 2008-11-26 MX MX2010005804A patent/MX2010005804A/es active IP Right Grant
- 2008-11-26 BR BRPI0819911A patent/BRPI0819911A2/pt not_active IP Right Cessation
- 2008-11-26 AU AU2008331102A patent/AU2008331102B2/en not_active Ceased
- 2008-11-26 CA CA2744736A patent/CA2744736C/en not_active Expired - Fee Related
- 2008-11-26 ES ES08855517.2T patent/ES2642873T3/es active Active
- 2008-11-26 WO PCT/IL2008/001546 patent/WO2009069126A1/en active Application Filing
- 2008-11-26 US US12/323,779 patent/US8273731B2/en not_active Expired - Fee Related
- 2008-11-26 SI SI200831872T patent/SI2224917T1/sl unknown
- 2008-11-26 JP JP2010534598A patent/JP5456687B2/ja not_active Expired - Fee Related
- 2008-11-26 HU HUE08855517A patent/HUE035105T2/en unknown
-
2012
- 2012-08-24 US US13/593,911 patent/US8921356B2/en not_active Expired - Fee Related
-
2014
- 2014-11-26 US US14/554,660 patent/US20150306109A1/en not_active Abandoned
-
2016
- 2016-09-08 US US15/259,752 patent/US20170128432A1/en not_active Abandoned
-
2017
- 2017-10-04 HR HRP20171476TT patent/HRP20171476T1/hr unknown
- 2017-10-04 CY CY20171101027T patent/CY1119768T1/el unknown
- 2017-11-30 US US15/827,293 patent/US20180303818A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20090149446A1 (en) | 2009-06-11 |
CN101925352A (zh) | 2010-12-22 |
US20180303818A1 (en) | 2018-10-25 |
AU2008331102A1 (en) | 2009-06-04 |
PT2224917T (pt) | 2017-10-17 |
SI2224917T1 (sl) | 2017-12-29 |
ES2642873T3 (es) | 2017-11-20 |
MX2010005804A (es) | 2010-11-30 |
AR069752A1 (es) | 2010-02-17 |
CA2744736A1 (en) | 2009-06-04 |
KR20100105841A (ko) | 2010-09-30 |
US8273731B2 (en) | 2012-09-25 |
US20170128432A1 (en) | 2017-05-11 |
CN101925352B (zh) | 2016-03-16 |
KR101613742B1 (ko) | 2016-04-19 |
BRPI0819911A2 (pt) | 2017-06-13 |
CL2008003507A1 (es) | 2009-11-27 |
HUE035105T2 (en) | 2018-05-02 |
EP2224917B1 (en) | 2017-07-05 |
AU2008331102B2 (en) | 2014-04-10 |
CY1119768T1 (el) | 2018-06-27 |
US20150306109A1 (en) | 2015-10-29 |
US8921356B2 (en) | 2014-12-30 |
DK2224917T3 (en) | 2017-10-16 |
LT2224917T (lt) | 2017-12-27 |
JP2011504490A (ja) | 2011-02-10 |
EP2224917A1 (en) | 2010-09-08 |
WO2009069126A1 (en) | 2009-06-04 |
HRP20171476T1 (hr) | 2017-12-15 |
US20130172321A1 (en) | 2013-07-04 |
JP5456687B2 (ja) | 2014-04-02 |
CA2744736C (en) | 2015-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LT2224917T (lt) | Kompozicija, apimanti nikotiną ir opipramolį, ir jos panaudojimas | |
AP2965A (en) | Therapeutic compositions and the use thereof | |
AP2490A (en) | Therapeutic compositions and the use thereof | |
GB0701426D0 (en) | Compounds and their use | |
EP2128196A4 (en) | POLYMERIC COMPOSITION AND APPLICATION THEREOF | |
ZA201004239B (en) | 4-(4-cyano-2-thioaryl)dihydropyrimidinones and use thereof | |
PL2066408T3 (pl) | Kompozycja na bazie ksantoksyliny i jej zastosowanie w kosmetyce | |
GB0717376D0 (en) | Composition and manufacture thereof | |
EP2077262A4 (en) | IMINOPYRIDINE DERIVATIVES AND THEIR USE | |
EP2213675A4 (en) | PYRIDOOXAZEPINE DERIVATIVE AND USE THEREOF | |
PL2012805T3 (pl) | Kompozycja lecznicza i jej zastosowanie | |
EP2069371A4 (en) | ORGANO ARSENOXIDE COMPOUNDS AND THEIR USE | |
EP2133326A4 (en) | NEW PSEUDOGLYCOLIPID AND ITS USE | |
GB0718718D0 (en) | Compound and use thereof | |
ZA200807390B (en) | Topical composition and use thereof | |
GB0714500D0 (en) | composition and treatment | |
GB2461611B (en) | Composition and use thereof | |
EP2168951A4 (en) | AZOLYLMETHYLIDENHYDRAZINE DERIVATIVE AND ITS USE | |
IL205998A (en) | Preparations that include nicotine and opipramol and methods for using them | |
HUP0600122A2 (en) | New compounds and their use | |
GB0711036D0 (en) | Composition and their use | |
GB0808877D0 (en) | Composition and use thereof | |
GB0810409D0 (en) | Composition and use thereof | |
GB0720518D0 (en) | Compositions and their use | |
GB0720524D0 (en) | Compositions and their use |